STAAR Surgical Company (STAA) Q3 2024 Earnings Call Transcript Summary
STAAR Surgical Company (STAA) Q3 2024 Earnings Call Transcript Summary
GAAP net income for Q3 2024 was $10 million, demonstrating growth from $4.8 million in the prior year.The following is a summary of the STAAR Surgical Company (STAA) Q3 2024 Earnings Call Transcript:
以下是staar surgical公司（STAA）2024年第三季度業績會交易摘要：
Financial Performance:
金融業績：
STAAR Surgical reported Q3 2024 net sales of $88.6 million reflecting a 10% increase year-over-year.
Gross profit reached $68.5 million or 77.3% of net sales.
GAAP net income for Q3 2024 was $10 million, demonstrating growth from $4.8 million in the prior year.
Adjusted EBITDA for Q3 2024 was $16.2 million or $0.33 per diluted share, maintaining a stable performance compared to $16.5 million or $0.33 per diluted share in the prior year.
STAAR Surgical報告2024年第三季度淨銷售額爲8860萬美元，同比增長10%。
毛利潤達到6850萬美元，佔淨銷售額的77.3%。
2024年第三季度的GAAP淨利潤爲1000萬元，顯示出與前一年480萬元的增長。
2024年第三季度調整後的EBITDA爲1620萬美元，每股攤薄盈利爲0.33美元，與前一年的1650萬美元或每股攤薄盈利0.33美元相比，表現穩定。
Business Progress:
業務進展：
STAAR opened a new EVO ICL Experience Center to enhance training and educational programs.
Achieved significant market share gains and global sales growth despite a challenging macroeconomic environment.
Hosted numerous international training programs and participated actively in industry events to bolster market presence and adoption of EVO ICL lenses.
STAAR開設了新的EVO ICL體驗中心，以增強培訓和教育計劃。
儘管面臨挑戰性的宏觀經濟環境，公司取得了顯著的市場份額增長和全球銷售增長。
舉辦了許多國際培訓項目，並積極參與行業活動，以增強EVO ICL隱形眼鏡的市場存在和採用。
Opportunities:
機會：
The company reported strong global adoption and market share gains of EVO ICL lenses, which positions it favorably in the expanding market.
Positive market reception and increased market share in the Americas, EMEA, and APAC regions.
Plans to launch at least 10 programs at the new center of excellence by year-end, aiming to bolster EVO ICL adoption and surgeon training.
公司報告了EVO ICL隱形眼鏡在全球的強勁採用和市場份額增長，這使其在不斷擴大的市場中佔據了有利位置。
美洲、歐洲、中東、非洲和亞太地區市場對市場的積極接納和市場份額增加。
計劃在年底前至少在新卓越中心推出10個項目，旨在增強EVO ICL的採用和外科醫生培訓。
Risks:
風險：
Sales in China softened in Q3 due to a declining macroeconomic environment, impacting overall momentum for that period.
The U.S. refractive market was more challenging than anticipated, with broader market conditions being down year-over-year.
由於經濟環境下滑，導致中國在第三季度銷售疲軟，影響了該時期的整體勢頭。
美國的屈光市場比預期更具挑戰性，整體市場情況同比下降。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
